Labcorp Holdings Past Earnings Performance
Past criteria checks 0/6
Labcorp Holdings's earnings have been declining at an average annual rate of -12%, while the Healthcare industry saw earnings growing at 10.6% annually. Revenues have been declining at an average rate of 0.6% per year. Labcorp Holdings's return on equity is 5.3%, and it has net margins of 3.4%.
Key information
-12.0%
Earnings growth rate
-10.2%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | -0.6% |
| Return on equity | 5.3% |
| Net Margin | 3.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Labcorp Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 12,713 | 436 | 2,179 | 0 |
| 30 Jun 24 | 12,488 | 450 | 2,136 | 0 |
| 31 Mar 24 | 12,300 | 399 | 2,084 | 0 |
| 31 Dec 23 | 12,162 | 379 | 2,032 | 0 |
| 30 Sep 23 | 12,058 | 583 | 1,944 | 0 |
| 30 Jun 23 | 11,868 | 677 | 1,872 | 0 |
| 31 Mar 23 | 11,757 | 789 | 1,798 | 0 |
| 31 Dec 22 | 11,864 | 1,002 | 1,763 | 0 |
| 30 Sep 22 | 12,990 | 1,518 | 1,851 | 0 |
| 30 Jun 22 | 14,186 | 1,829 | 1,918 | 0 |
| 31 Mar 22 | 15,104 | 2,028 | 1,944 | 0 |
| 31 Dec 21 | 13,136 | 2,195 | 1,690 | 0 |
| 30 Sep 21 | 16,555 | 2,763 | 1,894 | 0 |
| 30 Jun 21 | 16,388 | 2,879 | 1,787 | 0 |
| 31 Mar 21 | 15,316 | 2,643 | 1,718 | 0 |
| 31 Dec 20 | 13,979 | 1,556 | 1,729 | 0 |
| 30 Sep 20 | 12,442 | 845 | 1,550 | 0 |
| 30 Jun 20 | 11,475 | 362 | 1,535 | 0 |
| 31 Mar 20 | 11,587 | 321 | 1,523 | 0 |
| 31 Dec 19 | 11,555 | 824 | 1,625 | 0 |
| 30 Sep 19 | 11,389 | 755 | 1,521 | 0 |
| 30 Jun 19 | 11,292 | 853 | 1,496 | 0 |
| 31 Mar 19 | 11,276 | 896 | 1,490 | 0 |
| 31 Dec 18 | 11,333 | 884 | 1,578 | 0 |
| 30 Sep 18 | 11,291 | 1,414 | 1,504 | 0 |
| 30 Jun 18 | 11,081 | 1,266 | 1,483 | 0 |
| 31 Mar 18 | 10,743 | 1,217 | 1,458 | 0 |
| 31 Dec 17 | 10,308 | 1,227 | 1,499 | 0 |
| 30 Sep 17 | 9,951 | 724 | 1,436 | 0 |
| 30 Jun 17 | 9,702 | 732 | 1,471 | 0 |
| 31 Mar 17 | 9,556 | 751 | 1,522 | 0 |
| 31 Dec 16 | 9,553 | 712 | 1,306 | 0 |
| 30 Sep 16 | 9,295 | 658 | 1,592 | 0 |
| 30 Jun 16 | 9,192 | 633 | 1,652 | 0 |
| 31 Mar 16 | 9,029 | 599 | 1,556 | 0 |
| 31 Dec 15 | 8,506 | 438 | 1,469 | 0 |
| 30 Sep 15 | 7,774 | 447 | 1,360 | 0 |
| 30 Jun 15 | 7,056 | 430 | 1,213 | 0 |
| 31 Mar 15 | 6,353 | 401 | 1,204 | 0 |
| 31 Dec 14 | 6,012 | 511 | 1,181 | 0 |
| 30 Sep 14 | 5,936 | 518 | 1,164 | 0 |
| 30 Jun 14 | 5,846 | 529 | 1,143 | 0 |
| 31 Mar 14 | 5,798 | 540 | 1,131 | 0 |
| 31 Dec 13 | 5,808 | 574 | 1,129 | 0 |
Quality Earnings: N6B has a large one-off loss of $477.1M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: N6B's current net profit margins (3.4%) are lower than last year (4.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: N6B's earnings have declined by 12% per year over the past 5 years.
Accelerating Growth: N6B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: N6B had negative earnings growth (-25.3%) over the past year, making it difficult to compare to the Healthcare industry average (40.5%).
Return on Equity
High ROE: N6B's Return on Equity (5.3%) is considered low.